Research programme: early research therapeutics - ENYO Pharma/Inserm

Drug Profile

Research programme: early research therapeutics - ENYO Pharma/Inserm

Alternative Names: EBOLACURE; MIMESIS

Latest Information Update: 16 Dec 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ENYO Pharma
  • Developer ENYO Pharma; INSERM
  • Class Anti-infectives; Antineoplastics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Influenza virus infections
  • Research Cancer; Ebola virus infections; Viral infections

Most Recent Events

  • 12 Dec 2016 Early research in Influenza viral infections in France (PO) before December 2016
  • 12 Dec 2016 Preclinical trials in Influenza virus infections in France (IV) before December 2016
  • 06 Dec 2016 Early research in Cancer in France before December 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top